Helicobacter pylori in patients with functional dyspepsia and peptic ulcer disease: Possibilities of eradication therapy
https://doi.org/10.33667/2078-5631-2022-12-12-14
Abstract
Helicobacter pylori (HP) is a significant etiological factor in the development of diseases of the gastroduodenal zone (GDZ), the eradication of HP leads to a faster elimination of clinical symptoms of the disease, reduces the risk of stomach cancer and various complications. The aim of the study is to clarify the prevalence of HP in patients with GDZ pathology, the possibility of diagnostic methods for the detection of НР and the ongoing eradication therapy of this infectious agent. 205 patients were examined, in whom the presence of HP was studied by a combination of several methods and the appointment of eradication therapy when this infectious agent was detected, with clarification of its effectiveness. The results of the study showed a high prevalence of НР in the examined patients, which was about 80 %. HP diagnostics should be carried out using a combination of several methods, which allows obtaining more reliable results. About 20 % of patients have received eradication antihelicobacter therapy in the past. The low efficiency of which was due to non-compliance with the recommendations of treatment. The use of eradication antihelicobacter therapy prescribed by clinical recommendations gives a high percentage of cure. The frequency of side effects is quite low.
About the Authors
L. A. Fomina
Tver State Medical University
Russian Federation
Russian Federation
Fomina Lyudmila A., PhD Med, associate professor at Dept of Faculty Therapy
Tver
E. P. Dulneva
Tver State Medical University
Russian Federation
Russian Federation
Dul’neva Elizaveta P, assistant at Dept of Faculty Therapy
Tver
References
1. Minushkin O. N., Zverkov I. V. New approaches to eradication treatment of patients with duodenal ulcer associated with Helicobacter pylori. Medical Advice. 2017; (20): 87–90. DOI: 10.21519/2079–701Х-2017–20–87–90.
2. Voinovan I. N., Embutnieks Yu.V., Mareeva D. V. H. pylori as a risk factor for gastric cancer: evidence base and strategy for primary prevention. Almanac of Clinical Medicine. 2019; 47 (6): 535–547. DOI: 10.18786/2072–0505–2019–47–052.
3. Butov M. A., Zhestkova T. V., Karpova L. I. Comparative characteristics of the efficacy and tolerability of 10and 14-day courses of eradication therapy in patients with diseases associated with Helicobacter pylori. Kremlin Medicine. Clinical Bulletin. 2019; (2): 47–50. DOI: 10.26269/7vp2-dz50.
4. European registry of Helicobacter Pylori (protocol HP-eureg): first results of Russian centers. Bordin D. S., Yanova O. B., Abdulkhakov R. A. and others. Evidence-Based Gastroenterology. 2016; 5(1): 9–15.
5. Bakulina N. V., Simanenkov V. I., Bakulin I. G., et al. Descriptive epidemiology of H. pylori infection in patients with dyspepsia. Bulletin of the All-Russian Society of Specialists in Medical and Social Expertise, Rehabilitation and the Rehabilitation Industry. 2017; (2): 82–87.
6. Zhestkova T. V., Butov M. A., Krupnov N. M., etc. The frequency of detection of Helicobacter pylori in patients with morphological changes in the gastric mucosa. Experimental and Clinical Gastroenterology. 2021; 187 (3): 125–129. DOI: 10.31146/1682–8658-ecg-187–3–125–129.
7. Lazebnik L.B., Bordin D. S., Dekhnich N.N. and others. The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Memorandum. Experimental and Clinical Gastroenterology. 2021; 187 (3): 83–96. DOI: 10.31146/1682–8658-ecg-187–3–83–96.
8. Maev I. V., Kucheryavy Yu.A., Andreev D. N. Actual possibilities of optimizing antihelicobacter therapy. Attending Doctor. 2014; (4): 73–78.
9. Minushkin O. N., Topchiy T. B., Chebotareva A. M. The use of bismuth preparations in the treatment of gastroenterological patients and eradication schemes, taking into account the recommendations of Maastricht V. Medical Council. 2017; (15): 18–22. DOI: 10.21518/2079–701X-2017–15–18–22.
10. Chernin V. V., Chervinets V. M., Bazlov S. N. The place of Helicobacter pylori in the normomicrobiocenosis and dysbacteriosis of the mucosal microflora of the esophagogastroduodenal zone, the development of peptic ulcer, gastritis and esophagitis. Experimental and Clinical Gastroenterology. 2016; (2): 79–86.
Review
For citations:
Fomina L.A., Dulneva E.P. Helicobacter pylori in patients with functional dyspepsia and peptic ulcer disease: Possibilities of eradication therapy. Medical alphabet. 2022;(12):12-14. (In Russ.) https://doi.org/10.33667/2078-5631-2022-12-12-14
Views:
375
Email this article 